EGFR (R999A)
Sign in to save this workspaceEGFR · Variant type: point · HGVS: p.R999A
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Canertinib | 99.8% | 0.2% | 96.49 |
| 2 | Mobocertinib | 99.4% | 0.6% | 97.22 |
| 3 | Lazertinib | 99.4% | 0.6% | 97.47 |
| 4 | Neratinib | 99.3% | 0.7% | 93.18 |
| 5 | Erlotinib | 99.3% | 0.7% | 99.75 |
| 6 | Pralsetinib | 99.2% | 0.8% | 93.43 |
| 7 | Vandetanib | 98.9% | 1.1% | 95.74 |
| 8 | Zanubrutinib | 96.4% | 3.6% | 98.24 |
| 9 | Defactinib | 94.6% | 5.4% | 92.68 |
| 10 | Pacritinib | 79.0% | 21.0% | 88.64 |
| 11 | Alpelisib | 76.8% | 23.2% | 97.22 |
| 12 | Gilteritinib | 59.9% | 40.1% | 88.97 |
| 13 | Pirtobrutinib | 43.0% | 57.0% | 99.49 |
| 14 | Pemigatinib | 41.3% | 58.7% | 98.23 |
| 15 | Capmatinib | 38.2% | 61.8% | 99.75 |
| 16 | Avapritinib | 34.0% | 66.0% | 97.73 |
| 17 | Apatinib | 24.4% | 75.6% | 97.73 |
| 18 | Tivozanib | 20.6% | 79.4% | 92.42 |
| 19 | Tenalisib | 15.6% | 84.4% | 97.98 |
| 20 | Umbralisib | 15.4% | 84.6% | 98.74 |
| 21 | Fedratinib | 11.2% | 88.8% | 96.21 |
| 22 | Pexidartinib | 10.8% | 89.2% | 99.49 |
| 23 | Sorafenib | 9.9% | 90.1% | 96.72 |
| 24 | Idelalisib | 9.4% | 90.6% | 100.00 |
| 25 | Entrectinib | 9.0% | 91.0% | 93.69 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Canertinib | 99.8% | 98.4% | +1.4% |
| Mobocertinib | 99.4% | 100.0% | -0.6% |
| Lazertinib | 99.4% | 100.0% | -0.6% |
| Neratinib | 99.3% | 100.0% | -0.7% |
| Erlotinib | 99.3% | 99.4% | -0.2% |
| Pralsetinib | 99.2% | 99.1% | +0.0% |
| Vandetanib | 98.9% | 99.3% | -0.5% |
| Zanubrutinib | 96.4% | 88.2% | +8.2% |
| Defactinib | 94.6% | 94.6% | +0.0% |
| Pacritinib | 79.0% | — | — |
| Alpelisib | 76.8% | — | — |
| Gilteritinib | 59.9% | 91.0% | -31.2% |
| Pirtobrutinib | 43.0% | — | — |
| Pemigatinib | 41.3% | — | — |
| Capmatinib | 38.2% | — | — |
| Avapritinib | 34.0% | — | — |
| Apatinib | 24.4% | — | — |
| Tivozanib | 20.6% | — | — |
| Tenalisib | 15.6% | — | — |
| Umbralisib | 15.4% | — | — |
| Fedratinib | 11.2% | — | — |
| Pexidartinib | 10.8% | — | — |
| Sorafenib | 9.9% | — | — |
| Idelalisib | 9.4% | — | — |
| Entrectinib | 9.0% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 17.9ms